Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
43741
-
43742
Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial
Published 2018“…</p><p>Trial registration</p><p><a href="https://clinicaltrials.gov/ct2/show/NCT00554671" target="_blank">NCT00554671</a> ClinicalTrials.gov</p></div>…”
-
43743
-
43744
-
43745
-
43746
-
43747
-
43748
Mdm2 is involved in the maintenance of mitochondrial biogenesis and bioenergetics.
Published 2017“…<p>(A) Expression levels of selected factors from top-ranked gene sets identified in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189861#pone.0189861.g004" target="_blank">Fig 4A</a> that play a crucial role in the regulation of mitochondrial function and fatty acid oxidation as analyzed by RT-qPCR. …”
-
43749
-
43750
CONSORT flow diagram.
Published 2023“…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
-
43751
Baseline demographics.
Published 2023“…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
-
43752
Baseline health characteristics.
Published 2023“…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
-
43753
-
43754
Stoichiometry, polarity, and organometallics in solid-phase extracted dissolved organic matter of the Elbe-Weser estuary
Published 2018“…<div><p>Dissolved organic matter (DOM) is ubiquitous in natural waters and plays a central role in the biogeochemistry in riverine, estuarine and marine environments. …”
-
43755
WIN reduced bone resorption and MMP-9-activity in a capsaicin sensitive manner.
Published 2012“…Additional treatment with capsaicin (CIC) antagonized this decrease. Data are shown as means +/− SD, n = 5. (b) MMP-9-activity-ELISA of conditioned medium of osteoclasts. …”
-
43756
Scenarios analysed.
Published 2024“…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
-
43757
Post- diagnosis CRC survival model (Australia).
Published 2024“…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
-
43758
Model outputs used to inform this study.
Published 2024“…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
-
43759
Phenotypic and genotypic analysis following treatment of incrossed heterozygous <i>bmp4</i><sup><i>st72/+</i></sup> zebrafish with 0 μM, 0.25 μM and 0.5 μM PTC124.
Published 2019“…Error bars show standard error of the mean. We tested for trend in the probability of tail fin defects across the increasing doses of 0 μM, 0.25 μM and 0.5 μM PTC124 treated, groups of homozygous larvae [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0212121#pone.0212121.ref024" target="_blank">24</a>]. …”
-
43760